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EFFECTS OF CLINICAL RESEARCH PARTICIPATION ON DISEASE 
PROGRESSION IN CYSTIC FIBROSIS 
ROBERT FOWLER 
 
ABSTRACT 
 
CF is an autosomal recessive disorder caused by mutations in the CFTR gene. The 
life expectancy for patients with CF remains severely shortened, with the median 
predicted survival for patients currently estimated at 36.5 years. For patients with a life-
limiting disease such as CF, the decision to participate in a clinical trial is often based on 
the desire to improve quality of life and/or increase the likelihood of long-term survival. 
Recent advances in CF care have increased the number of therapies available for CF 
patients which in turn has increased life expectancy and diminished disease progression. 
The CFF has developed a patient registry and has worked with individual CFF-
accredited care centers in the US to approach all patients followed at these CF centers to 
participate in an observational prospective cohort study. Using data from 504 patients 
followed at Boston Children’s Hospital and submitted to the data registry maintained by 
the CFF, we examined disease progression, as measured by the decline in pulmonary 
function tests between 2007 and 2012 and compared multiple subsets of CF patients: 
those who participated in interventional studies, those who participated in observational 
studies only, and those who did not participate in any research studies. Results suggest a 
lower amount of lung function decline for adults who participate in interventional trials; 
however, the opposite pattern is true for children, with a higher amount of lung function 
decline seen for children who participate in interventional trials.  
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INTRODUCTION 
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF is one of the most 
common inherited diseases affecting approximately 28,000 patients in the United States 
and approximately 36,000 patients across the world. 
1
 CF is the most common fatal 
genetic disease in persons of European descent 
2 
(and estimated survival in the US is 
reported as 36.5 years.
3 
The mutations in CFTR cause reduced chloride transport, as well 
as associated water transport abnormalities because of increased viscosity of the 
secretions and exocrine gland dysfunction across the epithelium in the lungs, pancreas, 
liver, and intestines.   
CF primarily affects the lungs but also affects multiple other organs including the 
paranasal sinuses, intestines, and liver. Reduced chloride transport across the cell 
membranes results in a build-up of tenacious mucus in the lungs of CF patients, as well 
as pancreatic enzyme insufficiency, hepatic and biliary abnormalities, intestinal 
obstruction, and reduced fertility due to absence of the vas deferens in males and delayed 
puberty/menarche in females. This abnormal mucus leads to increased cycles of infection 
and inflammation of the airways leading to progressive and irreversible lung damage, 
predominantly bronchiectasis. CF patients usually require intensive, lifelong therapy 
including oral and inhaled medications, antibiotic treatment, and digestive enzyme 
capsules. The life expectancy for patients with CF is severely shortened. Most therapies 
focus on slowing the rate of disease progression and treating symptoms. 
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CF is diagnosed based on the evaluation of sodium chloride secretion, or 
sequencing of the CFTR gene to confirm the presence of two known CF causing 
mutations. A sweat chloride of greater than 60 mEq/L is determined to be a positive 
sweat test, although a positive sweat test is not sufficient by itself to diagnose CF in the 
absence of CF disease manifestations such as sinusitis or pancreatic insufficiency.
4, 5
 
Sequencing of the CFTR gene is now available commercially and is part of the standard 
screening panel in all 50 states.  
There are approximately 1800 known CFTR mutations that cause clinical 
phenotypes of CF.
6
 The mutations are grouped according to their molecular and 
functional effects on the CFTR gene. Different mutations can lead to reduced amounts of 
functional CFTR that reaches the cell surface through a) impaired cellular processing, b) 
reduced protein synthesis, or c) faulty delivery of proteins.
2
 CFTR gene mutations 
associated with minimal CFTR function include: defects in CFTR synthesis, defects in 
processing of CFTR and delivery to the cell surface, defects in the channel’s ability to 
open/close, and defects in channel conductance.
7, 8, 9
 
The most prevalent CF causing mutation is F508del, commonly referred to as 
deltaF508 or ΔF508. The mutation is an in-frame deletion in the CFTR gene resulting in 
a loss of phenylalanine at position 508.
10
 In the USA, almost 87% of patients with 
clinical CF have at least 1 copy of the F508del-CFTR mutation, and about 47% have 2 
copies.
11
 This mutation impairs the CFTR protein in multiple ways. The mutation can 
interfere with its ability to reach and stay on the cell surface, by impairing the protein 
folding and thus allowing the protein to be trafficked to the correct location on the cell 
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surface. The few proteins that do make it to the cell surface do not have the ability to 
open and close to allow chloride to pass through.
13, 14
 these deficits result in severely 
decreased chloride secretion.  
Because of the many mutations that may cause CF, and because of the variety of 
ways in which these mutations may cause dysfunction, disease severity is quite variable 
in CF. Pulmonary symptoms occur in greater than 90% of patients. The degree of 
pulmonary involvement is associated with decreased longevity.
14
 As early as 4 weeks of 
age, patients with CF begin to develop mucus plugging, neutrophilic invasion, and 
inflammation of airways.
15, 16
 High levels of the neutrophils in the airways and sputum 
contribute to persistent inflammation and airway obstruction,
 17
 and ultimately 
bronchiectasis.  
As a result of the layers of viscous mucus in the airways of CF patients and their 
coexistent inflammation, the lungs are an excellent environment for bacteria to grow. 
Many patients will develop chronic bacterial colonization/infection of the airways. The 
most common bacteria found in sputum cultures from patients with CF are Pseudomonas 
aeruginosa (PA), Haemophilus influenzae, Staphylococcus aureus, Burkholderia 
cepacia, and nontuberculous mycobacteria. Constant colonization and infection lead to 
pulmonary dysfunction and irreversible lung damage.  
Ultimately for CF patients, increased infection and inflammation in the lung leads 
to loss of lung capacity and eventually to respiratory failure and death. The median age of 
survival is projected to be ~35 years of age if all genotypes are considered 
11, 18
, but 
survival is generally shorter in patients with severe phenotypes.
19
Since 1990, the median 
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age of survival has almost doubled, in large part due to advances in CF care brought 
about by research organized and supported by the CFF. The CFF has become the 
paradigm for other orphan diseases in how they organize and implement clinical trials, 
and also create collaborations with pharmaceutical companies to continue to fund new 
research into CF.
 
Therapies for CF 
The therapeutic regimen for CF is aimed at slowing the progression of lung 
disease and loss of lung function by improving mucus clearance from the lung, treating 
bacterial infections and pulmonary exacerbations, and by supporting nutritional status 
through the use of pancreatic enzyme replacement therapy.
20 
The first FDA approved 
therapy specifically for CF was dornase alfa (Pulmozyme®), a mucolytic enzyme that 
hydrolyzes deoxyribonucleic acid (DNA), which is abundant from neutrophilic 
inflammation in CF airways
21
. Pulmozyme helps to hydrate the surface of the airway 
leading to less viscous secretions. Less viscous secretions allow the patient to move and 
clear mucus. Currently, two inhaled antibiotics are approved for treatment of 
Pseudomonas aeruginosa in CF; tobramyin inhalation solution (TOBI®)
 22, 23
, and 
aztreonam lysinate for inhalation (Cayston ®) 
24, 25
. CF patients are also often treated 
with courses of intravenous antibiotics in response to increased symptoms, also called 
pulmonary exacerbations.  
Recently a new medication has received regulatory approval for CF. Ivacaftor 
(Kalydeco™; 150-mg tablets) was developed by Vertex Pharmaceuticals as a CFTR 
potentiator. Ivacaftor was approved in the United States, the European Union, and 
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Canada in 2012 for the treatment of CF in patients 6 years of age and older who have a 
G551D mutation in the CFTR gene. The drug is an oral tablet that targets the underlying 
CFTR defect by increasing the channel gating activity of CFTR protein located at the cell 
surface. This restoration of chloride secretion allows for proper airway hydration 
resulting in a reduction on the cycle of inflammation, infection, and irreversible lung 
damage
26
.  
Ivacaftor is the first CFTR modulator to show an improvement in CFTR function 
and clinical benefit in patients with CF. Results from Phase 3 studies showed that 
ivacaftor is effective in the treatment of patients with CF who have the G551D-CFTR 
mutation, as evidenced by sustained improvements in CFTR channel function (measured 
by reduction in sweat chloride concentration) and corresponding substantial, durable 
improvements in lung function, pulmonary exacerbations, respiratory symptoms, and 
weight gain
26
. The G551D mutation is present in only about 4% of the CF population
55
.  
Modifiers of Disease Progression  
Bacterial Colonization - Pseudomonas Aeruginosa 
Acquisition of specific pathogens, namely Pseudomonas Aeruginosa (PA) and 
Burkholderia species can significantly alter the clinical course of the patient with CF.
26, 27, 
28
 PA is the most common and most significant bacteria associated with chronic airway 
colonization and infection in CF.
14
 Chronic PA infection is a significant predictor of 
mortality,
29
 has been associated with higher rates of pulmonary function decline, 
30
 and 
children with PA-positive respiratory cultures during the first year of a study had a 2.6-
fold increase in mortality over the subsequent 8 years of follow-up relative to children 
 6 
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who had PA-negative cultures.
31
 In the US, approximately 72% of CF patients 18 years 
or older are colonized with PA; with approximately 53% of the total CF population 
colonized with PA.
32
 Once colonization occurs, bacterial eradication is quite difficult, if 
not impossible. Colonization with PA can have dramatic effects on clinical outcome and 
disease progression. Chronically infected patients experience frequent infections and 
significant loss of lung function, which is due in large part to the inflammatory response 
to chronic bacterial infection.
33
 Li et. al. showed that early detection and eradication of 
PA is critical and there appears to be a window of opportunity for possible eradication. 
They also showed that mucoid PA, a phenotype of PA, plays a much greater role in CF 
lung disease progression than non-mucoid PA.
34 
Burkholderia species  
PA is the most common and extensively researched bacterial pathogen associated 
with CF pulmonary disease, however other organisms are often associated with more 
rapid decline in pulmonary status and lung function. The Burkholderia species are 
recognized as causing significant change in the clinical course of patients with CF. In 
2007 approximately 3% of CF patients were infected with Burkholderia. The prevalence 
of infection with Burkholderia was also 3% in 2012
11
 but there is a wide variety of types 
and range of prevalence across centers and regions. At Boston Children’s Hospital, the 
overall prevalence is approximately 10%. This increase in prevalence is primarily due to 
an outbreak of a specific type of Burkholderia species now called Burkholderia dolosa.  
In 1992, a patient infected with a type of burkholderia transferred to BCH. In 
2001, as genotyping improved, cultures previously characterized as Burkholderia 
 7 
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multivorans revealed an increasing incidence of a newly described genomovar, 
genomovar VI, burkholderia dolosa. Thirty-six patients ultimately became colonized with 
this bacteria, and only 18 are still living.
56
 
Certain strains of Burkholderia are more virulent than other strains and are 
associated with ~ 40% loss of FEV1 per year or a 2-year mortality rate of > 50%; these 
strains are considered the most serious because of their association with rapid progression 
to severe necrotizing pneumonia and death.
 35, 36, 37 
The most common Burkholderia 
species that infect CF patients are Burkholderia multivorans and Burkholderia 
cenocepacia;
38, 39, 40
 however, all species are associated with a marked clinical decline.  
Burkholderia species are inherently resistant to most antibiotics and are known to 
acquire resistance quickly when exposed to antibiotics. Despite advances in the care of 
patients with CF, there is no standard therapy for treating Burkholderia infection. Patients 
typically receive a combination of systemic, oral, or inhaled antibiotics frequently or even 
continuously for control of their symptoms. Since patients with Burkholderia infection 
frequently have rapid loss of lung function, they are often considered for lung 
transplantation. However, Burkholderia infection is associated with worse outcomes, and 
many transplant centers exclude or limit transplantation in these patients.
41 
Nontuberculous mycobacteria (NTM)  
Infections with NTM are also associated with a more rapid decline in lung 
function.
42 
Recovery of NTM from CF respiratory secretions is relatively common, with 
an overall prevalence of 13% reported in a large prospective study.
43
 More recent studies 
have suggested that the NTM prevalence in CF may be increasing.
44, 45 
It is hypothesized 
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that screening is becoming better and more routine, but also that the early treatment of 
PA is leading to colonization with other bacteria, including NTM. At Children’s Hospital 
Boston the overall prevalence is approximately 6-10%.  
Clinical Trial Participation 
In the last two decades there has been a dramatic shift in research toward evidence 
based medicine.
46
 Evidence based medicine places strong emphasis on the results of 
randomized clinical trials when determining individual patient treatment. This shift has 
seen a significant increase in the number of randomized, including placebo-controlled, 
clinical trials. The placebo-control group in a randomized clinical trial may receive no 
benefit from their participation, while it is hoped that the active drug group will receive 
the benefit of a new therapy that is as effective as or more effective than what is currently 
available.  
The most common reasons patients report for participating in clinical trials are in 
descending order: potential medical benefit, trust in physician/advice of physician, 
potential benefit to others, and study compensation/reduction in medical costs.
47 
Patients 
who decide not to participate in clinical research most often report they do not want to be 
randomized into a treatment arm, 
48 
do not view the risk/benefit ratio as favorable, do not 
have the time to commit to the study, do not wish to be a “guinea pig, “or have a distrust 
in drug research or their physician/medical facility in general. Previous research has 
shown that there are certain demographic factors that are more often associated with 
participation in clinical trials including; males, older, lower socio-economic status, 
 9 
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patients who have a higher level of trust in their physicians, and those who have a lower 
level of education 
23, 51, 52
 
 For patients with a life threatening illness or disease, the decision to participate in 
a clinical trial is often based on the desire to improve quality of life and/or increase the 
likelihood of long-term survival. However, a clinical trial is by definition experimental. 
The researchers are testing to determine if the new treatment has any effect on health 
outcomes.  
Previous research has shown improved outcomes for patients who participate in 
randomized clinical trial (RCT) regardless of treatment assignment. Davis et al 
49
 showed 
that patients with non-small cell lung cancer who participated in a RCT had significantly 
better survival rates than that of subjects not participating. Four of the five trials in a 
meta-analysis of cancer survival found that patients in trials survived significantly longer 
than patients not in trials.
50
 
Also, physicians who are actively involved in clinical research may be more 
aware of the results of trials and would be more likely to prescribe newer treatments. This 
suggests that receiving care at a facility where clinical research is conducted may be 
beneficial. Other research has shown that there is a psychological benefit in terms of 
better mood, more positive outlook, and decreased prevalence of mood symptoms when 
participating in clinical trials.
51, 52
 
Primary Aim 
This study examined the amount of disease progression as measured by loss of 
lung function, as defined by the forced expiratory volume in 1 second (FEV1) of CF 
 10 
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patients who participated in clinical research (both in observational/clinical trials vs. 
clinical trials only) and compares these groups against patients who did not participate in 
research of any kind. In this study participation in clinical trials is defined as enrollment 
in a clinical trial involving an investigational drug. Comparisons were made between the 
FEV1 of patients in these three groups in an attempt to measure the effect of trial 
participation. It was expected that patients who participated in clinical trials would have 
lower amounts of disease progression than those subjects who did not to participate in 
interventional research.  In the previous 5 years, BCH has conducted approximately 45 
interventional trials.  
Hypothesis 1  
It was hypothesized that participation in clinical trials would benefit subjects in 
multiple ways. First, subjects were provided access to new investigational drugs that 
could improve their health. Subjects participating in trials do not know whether they 
received the investigational drug or whether the drug was beneficial. However two recent 
medicines have recently received approval from the FDA for patients with CF. Many of 
the patients in the interventional group may have received one of these medications in the 
many trials undertaken at BCH.  
 Second, participation in clinical trials may lead to better adherence with the 
complicated CF medication regimen. The pulmonary team including doctors, nurses, and 
research coordinators evaluate the subjects more often compared to patients who do not 
participate in clinical trials. Study investigators and staff often provide education at study 
visits with regards to a participants’ medication regimen (especially during the trial). This 
 11 
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increased interaction may lead to better adherence with medications during a clinical 
trial. During participation in a clinical trial research coordinators and nurses asked about 
each medication the patient was taking at each visit to ensure subjects remained on a 
consistent regimen that allowed the trial to investigate the effect of the investigational 
drug. 
 Third it was hypothesized that clinical trial participation would improve the 
subjects overall mood and demeanor and might also increase their overall knowledge of 
their disease. These changes might therefore lead to improved lung function Because of 
infection control precautions in CF, the patient often does not speak to or interact with 
anyone other than their family regarding their disease. Through trial participation the 
patient/subject interacted with the research team on a frequent basis and had a chance to 
speak to someone who perhaps could understand their disease and could offer insight into 
disease specifics, difficulties, and problem-solving. The research team was very 
knowledgeable about CF and could often answer questions and provided information on 
clinical research in CF, which especially with the recent success of CF clinical trials may 
offer the patients hope and increased optimism for the future.  
Hypothesis 2: 
Lower amounts of disease progression were not expected in subjects who 
participated in observational studies when compared to subjects who did not participate 
in interventional research. There was little and no direct medical benefit to subjects who 
participated in observational studies, and thus differences in amount of disease 
progression were not expected.  
 12 
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METHODS 
This was a retrospective cohort study of CF patients ages 6 years and older 
followed at BCH. Since 1985, the CFF has asked all patients followed at CF centers 
nationwide to participate in a research study allowing the centers to enter medical 
information into a database. The CFF database includes more than 115 CF Care Centers 
across the United States, and approximately 30,000 patients. The purpose of the CF 
registry is to compile and maintain long-term epidemiological data for researchers and 
clinicials regarding medication use, clinical patterns outcomes, and mortality and 
morbidity rates. The BCH registry contains entries for approximately 550 patients dating 
back approximately 20 years. This study examined data from the previous six years.  
Data was collected at all clinic visits, admissions, and surgical procedures for all 
patients enrolled. The data collected included demographics (age, sex, marital status, 
education level), diagnostic information (sweat test values, form of diagnosis, age of 
diagnosis, CF genotype, CF clinical symptoms), morbidity data, pulmonary function test 
results, exacerbation history, microbiology results, and hospitalization dates. 
Using the CFF database, a query was generated for all spirometry data between 
the years 2007 and 2012. The query returned data on 504 individual patients with 15, 326 
spirometry results.  
Patient selection 
Cystic fibrosis patients who were ages 6 years and older, and for whom data were 
available were included in this study. The number of subjects followed at BCH was 556. 
Of note, 52 of the 556 patients followed at BCH were not included in this analysis 
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because they did not provide consent to participate in the CF registry study. The reasons 
for not participating included religious reasons, the inability to consent (language or 
developmental delay), the inability to contact (most often because of infrequent clinical 
visits), and general refusal to provide data to a registry. This patient population was 
generally healthier than patients who have provided consent and have far fewer clinical 
visits. Subjects who did not perform at least two spirometry measures in 4 of the 6 years 
in this group, were not included in the overall analysis as disease progression could not 
accurately be measured. This excluded 115 additional subjects.  
Disease Progression  
 Disease progression was quantified using results of pulmonary function tests 
(PFTs); specifically the forced expiratory volume in one second (FEV1), a standard 
measure of lung function. FEV1 is expressed as a percentage of a predicted value based 
on age, gender, race, and height. FEV1 is the most frequently used measure of disease 
status in CF and other obstructive lung diseases as well as the primary outcome measure 
in numerous CF clinical trials
26
. The measure is highly correlated with quality of life and 
mortality in CF. The average FEV1 was calculated for each year for each patient for 
calendar years 2007-2012. The amount of disease progression is the absolute difference 
between the average FEV1 from 2007 (or 2008 if no records are available for a specific 
patient in that year) and the average FEV1 from 2012 (or 2011 if no records are available 
for a specific patient in that year). 
Participant Groups 
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The interventional group included all subjects who participated in a clinical trial 
involving an investigational drug between 2007 and 2012 (other than expanded access 
programs). Patients participating in expanded access (compassionate use) programs have 
not been counted as participating in a clinical trial because although they have received 
an investigational drug; the drug was shown to have some benefit for this group and this 
group is also usually much sicker than the average patient. The observational group 
included all subjects who participated in observational research studies only (excluding 
subjects who participated in clinical trials) including surveys, sample collection, and any 
other non-interventional clinical trial. Of note, all patients who participated in clinical 
trials between 2007 and 2012 also participated in an observational trial. The third group 
included patients who had not participated in any research trials of any kind other than 
the CF registry.  
RESULTS 
The average FEV1 percent predicted was calculated for each year for each 
patient. 115 patients who did not have at least two spirometry measures performed in at 
least 4 of the years examined were not included in the analysis. The average FEV by year 
is shown in Table 1.0.  
The average FEV1 for the interventional group in 2007 was 82.9, standard 
deviation 22.78. The observational group average FEV1 in 2007 was 83.5%, standard 
deviation 23.76, the non-participant group was 86.9%, standard deviation 19.60. Baseline 
lung function on average in 2007 was no different across the 3 groups. The average FEV1 
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for the interventional group in 2012 was 74.4. The observational group average FEV1 in 
2012 was 78.4%, the non-participant group was 79.6%. The differences between each of 
the three groups were not statistically significant.  
The average age of the sample was 24.4 years, standard deviation 11.49. This was 
a slightly older sample than the entire CF population at Children’s Hospital Boston 
whose average age is 21.6 years. The likely explanation for that is that patients 6 years 
and younger do not generally perform spirometry and were not included in the analysis.  
The average ages of the interventional, observational, and the non-participants 
groups were 25.9, 24.4, and 24.2 years, respectively. In 2007 the average FEV1 for all 
adults was 77.66%, standard deviation 22.85, while for children it was 97.36%, standard 
deviation 15.62. Similarly, in 2012 the average FEV1 for the adults was 68.75%, standard 
deviation 24.45 and for children it was 93.25%, standard deviation 17.75. For adults in 
the interventional group the average FEV1 in 2007 was 76.8%, standard deviation 21.60 
and for children in the interventional group in 2007 the average was 99.36%, standard 
deviation 17.47. In 2012 the average FEV1 for adults was 68.5%, standard deviation 
20.52 and for children it was 88.1%, standard deviation 17.86.  
Of the 389 patients (see Table 1) included in the analysis, sixty-four patients had 
participated in interventional research trials between the years 2007-2012: 207 patients 
had participated in observational trials only, and 118 patients did not participate in any 
research studies (other than participation in the CFF registry). The average amount 
decline of lung function for subjects in the interventional group was 9.58%, standard 
deviation 10.12, between 2007 and 2012 compared to 8.27%, standard deviation 13.61, in 
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the observational group, and 8.33%, standard deviation 12.59, in the non-participant 
group. When controlling for number of years of data for each patient, the interventional 
group declined at a rate of 1.64% per year from 2007 to 2012 compared to 1.49% per 
year to all other patients. The observational group declined on average 1.89% per year 
and the non-interventional group declined 1.44% per year.  
There was no statistically significant difference between the amount of decline in 
the interventional group compared with observational group (t268) = 0.70, p = 0.47 or the 
non-interventional group (t181) = 0.68, p = 0.49. There was also no statistically 
significant difference in the rate of decline of the interventional group compared with 
observational group (t268) = 0.76, p = 0.45 or the non-interventional group (t181) = 0.61, 
p = 0.54. Ten of the 64 subjects who participated in clinical trials (15.63%, compared to 
12.05% ((47 of 389)) of the group in this analysis) were colonized with the specific 
organisms associated with a rapid decline. Of note, the sixty-four patients who 
participated in intervention trials performed on average 52 pulmonary function tests 
between 2007 and 2012, compared to 37 pulmonary function tests for all other patients.  
The effect of clinical trial participation for adults and children was examined 
separately (or in a stratified analysis) (See Figure 2.0). Adults in the interventional group 
experienced an average lung function decline of 8.86%, standard deviation 10.71 from 
2007 to 2012 standard deviation 14.40, compared to 10.24%, for adults in the 
observational group and 10.30% (standard deviation 11.50), for adults in the non-
interventional group. Adults in interventional group declined at a rate of 1.52% per year 
compared to 1.86% per year to all other adults. Adults in the observational group decline 
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at a rate of 1.91% per year and adults in the non-interventional group decline at a rate of 
1.78% per year.  
There was no significant difference in the amount of decline for adults in the 
interventional group compared with all other adults (t241) = 0.68, p = 0.50), or with each 
group specifically; observational (t163) = 0.58, p = 0.56), and non-interventional (t121) = 
0.68, p = 0.49). There was not a statistically significant difference in the rate of decline 
for adults in the interventional group compared to the observational and the non-
participant groups.   
The rate of disease progression between the three groups was different for 
children compared to adults. For children who participated in interventional trials, the 
average loss of lung function between 2007 and 2012 was 11.41%, standard deviation 
8.54,  compared to 5.28%, standard deviation 12.84, for all other children. The difference 
in quantity of decline for children in the interventional group compared to all other 
children was statistically significant (t144) = 2.06, p = 0.04). Children in the 
observational group declined on average 5.40% and children in the non-interventional 
group declined on average 4.47%. Both of these results when compared to the 
interventional group were statistically significant (t104) = 1.97, p = 0.05 and (t57) = 2.00, 
p = 0.05, respectively). Children in interventional group declined at a rate of 1.92% per 
year compared to 0.93% per year to all other children. Children in the observational 
group declined at a rate of 0.98% per year and children in the non-interventional group 
decline at a rate of 0.80% per year.  
DISCUSSION 
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Using data from 504 patients submitted to a data registry maintained by the Cystic 
Fibrosis Foundation, we examined disease progression, as measured by amount of 
decline in pulmonary function tests between 2007 and 2012 and compared multiple 
subsets of CF patients: those who participated in interventional studies, those who 
participated in observational studies only, and those who did not participate in research. 
There was no difference in the amount of decline in lung function between adults who 
participated in intervention trials and adults who did not. In contrast, children who 
participated in intervention trials had a significantly larger amount of decline of lung 
function than children in the observational and non-participant groups. This may be a 
result of several factors, including the possibility that the families of children who 
participate in research may looking for new and better treatments because they see the 
child’s health declining. Also, many inclusion criteria for studies do not allow children or 
adults with a certain level of FEV1; for example above 90%. Children who participate in 
research are often included because their lung function has already declined at a faster 
rate from that of other patients.  
Many patients choose to participate in clinical trials as a way to improve their 
quality of life in terms of better symptom control or increased monitoring of care. 
Research has shown that additional medical monitoring, the opportunity for a “second 
opinion” and the reassurances received were more important benefits than the physical 
improvement
58
. A recent study found that even those patients who do not medically 
benefit from a trial often found joining the clinical trial a meaningful experience in terms 
of benefiting future research. The experience of interacting with the research staff partly 
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influenced the final impression of the trial participation experience.
57
 Adults may also 
benefit from the trial more than children specifically through the interaction with the 
research staff. Often the attention of the research staff is divided when working with 
children between the patient and the family and or family members who are present 
during the visit. Adults often receive more attention from the research staff and this 
increased attention may be of benefit in itself to the patient.  
 This difference may also be explained by the effect of improved adherence to 
chronic therapies by individuals enrolled in research trials. The medication regimen for 
the younger patients is often supervised and overseen by the parents and generally 
compliance with medications is often higher in the younger age groups. Adults may 
improve their medication adherence during a clinical trial more than children who already 
have high levels of adherence. Also, the research staff may direct much of their attention 
and teaching to the parents regarding CF care, research, and problem solving leaving less 
benefit to a distracted child.  
Clinical trials may also be more beneficial for adults because trial participation for 
adults may be for a longer period of time. Many of the CF interventional trials with 
children are for shorter periods of time than the trials with adults. BCH primarily 
participates in Phase 2 and 3 studies with Phase 3 studies being the longest of the trials. 
Many of the Phase 3 studies will often start with subjects at least 12 years of age; 
excluding many of our pediatric participants. The Phase 2 studies in CF that do include 
ages 6 and up are first very short trials with few participants because of safety. Also, 
adult participants are eligible for more trials and have participated in a greater number of 
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trials than children at BCH in this time period. Adults participated on average in 1.60 
trials and children participated in 1.26 trials. Future research is needed to parse out the 
effect of clinical trial participation in CF; especially the different pattern seen in adults 
and children.    
Further research is needed to understand the relationship between disease 
progression in CF and participation in clinical research. This study did not control for 
other possible disease progression modifiers such as education, adherence to medication 
regimen, colonization with harmful bacteria, or genetics. Future studies  
If it were true that children who participate in clinical research have larger 
amounts of disease progression, families would need to strongly consider the decision to 
enroll a child in a clinical trial. More research would be needed to understand what the 
possible mechanism of action for this larger increase compared to the adult population. 
Sponsors and investigators would need to strongly examine trial design when enrolling 
children into trials. This researcher does not believe that clinical trial participation is 
harmful or results in worse disease outcomes; for children or adults. The result may most 
easily be explained by differences in the groups that participate in trials versus those who 
do not. We also know that in CF, the greatest amount of disease progression often occurs 
during the teenage/adolescent years. The difference we are seeing in terms of disease 
progression in adults versus children is not an affect of clinical trial participation, but 
simply an effect of the disease itself in the adolescent years.  
Children and adults who participate in research are participating because they 
often hope to receive some medical benefit from the trial. Patients and families are more 
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likely to participate if they recognize that they or their child is sick and that current 
medications and therapies are not effective. Patients who feel sick and have constant 
symptom burden are more likely to seek additional ways to improve their condition and 
participation in clinical trials offers that. Patients and families of CF patients who 
experience low symptom burden and overall better health are less likely to view research 
as a way to improve their lives.  
We hope that the investigational drugs being tested are of benefit themselves to 
the research subjects. But we also know that for those patients who receive placebo 
during a randomized trial, there may be benefit to them. Increased monitoring, increased 
interaction with medical and research staff, and the opportunity for a second opinion are 
potentials benefits of participation in a clinical trial. Research has shown that subjects 
who received placebo during a clinical trial of anti-thrombin therapy in premature infants 
had better outcomes than those infants who were eligible to participate in the trial but did 
not participate
59
. That is, there was a benefit to simply participating in the clinical trial 
itself on health outcomes in this population.  
Limitations 
There are several difficulties with this overall approach. First, patients who 
participate in clinical trials are often more adherent to their medications; both during the 
trial because of increased monitoring, and outside of the trial. Patients who participate in 
research may do so to please the physician and would follow their physician’s orders 
regarding medication use. Also, a different way to examine the effect of clinical trial 
participation on disease progression would be to examine the FEV1 change each year for 
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each patient and then to code each year that a patient participated in a trial versus the 
years that patients did not participate in trials. This method would allow the researcher to 
examine the effect of trial participation both within and across subjects.  
Also, the participants of interest in this study (the subjects in the interventional 
group) chose to participate in clinical trials. It is possible that these patients are sicker and 
declining more rapidly and may be more likely to want access to investigational drugs 
than patients whose clinical courses are much more stable. Lastly, the data analyzed in 
this study was only for a short period of time (2007 to 2012) at only one hospital. This 
time period was chosen because of the limited data available to the researcher and 
unfortunately a database is only as good as data entered. The overall number of subjects 
analyzed is small and additional work is needed to understand if these results hold true at 
other CF centers across the country.  
Conclusions 
Patients that participated in clinical trials at BCH between the years of 2007 and 
2012 did not have a significantly different amount of disease progression than subjects 
who did not participate in interventional trials (including patients who that participated in 
observational trials only and patients that did not participate in any research). There was a 
different pattern of disease progression when comparing adults and children. Children 
who participated in interventional trials had a larger amount of disease progression than 
children who did not while adults had a smaller amount of disease progression; although 
this did not meet clinical significance. 
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Table 1.0  
Demographics of All Subjects 
*Or first year of data collection if not 2007 
**Or last year of data collection if not 2012 
 
 
Group Number 
of 
Patients 
Average 
Age 
Number 
of 
Subjects 
 
Gender 
 
Average 
FEV1 
in 
2007* 
Standard 
Deviation 
in 2007 
Average 
FEV1 
in 
2012** 
Standard 
Deviation 
in 2012 
Interventional 
Group 
64 25.9 
(range 
12 -58) 
64 Males: 
29 
Females: 
35 
83.0 22.78 74.4 21.62 
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Observational 
Group 
207 24.4- 
(range 
10-71) 
207 Males: 
102 
Females: 
105 
83.4 23.76 78.4 26.15 
Non 
Participant 
Group 
118 24.2 
(range 
9-73) 
118 Males: 
63 
Females: 
55 
86.9 19.60 79.6 22.63 
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Table 
2.0  
 
 
 
 
 
 
 
 
 
Figure 1.0  
FEV 1 Percent Predicted between 2007 and 2012 
 Number Average FEV1 in 2007 Average FEV1 in 
2012 
Rate of Decline 
per Year 
 Adults Child
ren 
Adults Children Adults Childre
n 
Adults Childre
n 
Interventional  45 19 76.8(+/- 
21.6) 
 96.5 (+/- 
17.9) 
68.1 (+/- 
20.5) 
88.36 
(+/- 
17.5) 
1.52 1.92 
Observational  120 87 74.1 (+/- 
21.6) 
66.2 94.5 98.2 1.91 0.98 
Non 
Participant  
78 40 84.0 72.7 92.8 94.0 1.78 0.80 
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Figure 2.0: Rate of FEV1 Decline for Subjects by Group 
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